Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2010 - 2018)

Ironwood Pharmaceuticals has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $6.3 million in Q4 2018.

• Quarterly Non-Current Deffered Revenue rose 15.76% year-over-year to $6.3 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $6.3 million (up 15.76% YoY) and the FY2018 annual result came in at $6.3 million, up 15.76% from the prior year.
• Non-Current Deffered Revenue rose to $6.3 million in Q4 2018 per IRWD's latest filing, from $6.1 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $10.5 million in Q4 2014 and troughed at $557000.0 in Q4 2016.
• A 5-year average of $6.1 million and a median of $6.1 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2016 and 2017: Non-Current Deffered Revenue tumbled 91.29% in 2016, then soared 878.28% in 2017.
• Over 5 years, Non-Current Deffered Revenue stood at $10.5 million in 2014, then slumped by 39.22% to $6.4 million in 2015, then sank by 91.29% to $557000.0 in 2016, then jumped by 878.28% to $5.4 million in 2017, then increased by 15.76% to $6.3 million in 2018.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $6.3 million, $6.1 million, and $6.1 million for Q4 2018, Q3 2018, and Q2 2018 respectively.